A trial to study the effect of a medicine, Rivastigmine for memory loss in a disease of the Central Nervous System Multiple Sclerosis
Phase 3
Completed
- Conditions
- Health Condition 1: G00-G09- Inflammatory diseases of the central nervous system
- Registration Number
- CTRI/2019/03/018291
- Lead Sponsor
- AMRITA GOTUR
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 60
Inclusion Criteria
1. Written informed consent to participate in the trial.
2. Males and Females between 18 yrs and 65 yrs of age
3. Definite diagnosis of Multiple Sclerosis as defined by 2017 Revised Mc Donald Criteria
4. Sufficient education to read, write and communicate comprehensibly.
Exclusion Criteria
-Relapse in the recent 2 months
-Presence of systemic disease affecting cognition ( stroke, head trauma, PD),
-Presence of neuropsychiatric conditions affecting cognition ( major depression ),
-Those who refuse consent
-Pregnant and lactating women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method